|
With good support from:
Pierre Fabre Pharma GmbH, Freiburg in Breisgau
Advanced BRAF– V600E mutant NSCLC
With the combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib, targeted treatment for advanced disease has been available since August 2024 BRAF-V600E mutated non-small cell lung carcinoma (NSCLC). Approval in the European Union (EU) was based on data from the PHAROS study, in which the combination achieved a response rate of 75% in first line and thus provided relevant clinical benefit. This combination therapy is easy to administer and shows a tolerability profile consistent with previous experience with melanoma[1].